Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05096728 · ClinicalTrials.gov registry record
Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)
A clinical trial of Preeclampsia With Severe Features, sponsored by Ohio State University.
- Completed
- Registry status
- 56
- Enrollment target
- 1
- Study location
NCT05096728 is a study of Preeclampsia With Severe Features that has completed, run by Ohio State University. The registered enrollment target is 56 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05096728, a study of Preeclampsia With Severe Features, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose a randomized controlled unblinded trial to evaluate rates of optimal blood pressure control between Nifedipine 60mg XL once daily vs. Nifedipine 30mg XL twice daily in patients admitted for expectant management with pre-eclampsia with severe features. Patients will be approached for consent when they are placed on 30mg of Nifedipine daily by their primary provider and will be enrolled in the study when the primary provider has made the decision to increase the patient's daily dose of Nifedipine XL from 30mg to 60mg.
Conditions Studied
Interventions
- DRUG Nifedipine XL
Study Locations (1)
Ohio
- The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2023-12-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05096728
The ClinicalTrials.gov registry entry for NCT05096728 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Preeclampsia With Severe Features appearing as the primary indexed condition, and to 1 intervention - of which Nifedipine XL is the first listed.
NCT05096728 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05096728 about?
NCT05096728 is a clinical study titled "Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)". The investigators propose a randomized controlled unblinded trial to evaluate rates of optimal blood pressure control between Nifedipine 60mg XL once daily vs. Nifedipine 30mg XL twice daily in patients admitted for expectant management with pre-eclampsia with severe features. Patients will be appro...
What is the current status of trial NCT05096728?
This trial is currently completed. The enrollment target is 56 participants. The study started on 2021-12-01. Estimated completion is 2023-12-15.
What conditions does trial NCT05096728 study?
This clinical trial studies the following conditions: Preeclampsia With Severe Features.
What interventions are being tested in trial NCT05096728?
The interventions under investigation include: Nifedipine XL (DRUG).
Who is sponsoring clinical trial NCT05096728?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05096728 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.